💡 Could This Be THE KEY to BRAIN Health?

Name: 💡 Could This Be THE KEY to BRAIN Health?
Uploaded: 2025-02-17T17:00:21+00:00
Duration: 57 s
Channel: Claudia von Boeselager
Description: In this segment, the speaker explains that three leading neuroscience research groups have identified mitophagy—the cellular process that removes damaged…

17 Feb 2025 · 1 min

Watch on YouTube

0:57

In this segment, the speaker explains that three leading neuroscience research groups have identified mitophagy—the cellular process that removes damaged mitochondria—as the most down‑regulated pathway in the brains of Alzheimer’s disease and dementia patients. In response, researchers have screened repurposed, longevity, and natural compounds, finding that urolithin A consistently shows strong protective effects in pre‑clinical Alzheimer’s models. Building on these findings, the speaker’s team has launched a randomized clinical trial that does not target dementia directly but instead enrolls 50‑year‑old individuals experiencing brain energy deficits, aiming to test whether urolithin A can improve neuronal mitochondrial function. The trial is newly initiated, with results expected next year, and the speaker expresses cautious optimism about its potential.

Chapters

We got interested in Brain because of the research being done by 3 really top neuroscience and cognitive health research groups in the world. They all almost at the same time published that in the brains of Alzheimer's and dementia patients, the number 1 pathway that was down was actually mitophagy in the neurons and the brain cells. And so they started looking at all kinds of repurposed drugs, longevity drugs, natural molecules, and they all kind of unanimously came and found that in these early, let's say, preclinical models of Alzheimer's, the one molecule that was showing a lot of promise was urolithin A. And so we got obviously interested because a lot of these guys, folks, professors came to us and said, we wanna run a clinical trial. So we have actually now designed a trial that we have just started, which is not going after dementia, but going after the 50-year-olds who have brain energy issues. So we'll see if this is a randomized trial that probably will have data next year. But it sounds very promising. Sounds very promising.